---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068534"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:39:18.339856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive

## Summary
- Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.
- Cash, cash equivalents and investments of $106.9M expected to fund operations into 2027.
- LX2006 in FA cardiomyopathy: interim data show 25% mean LVMI reduction and 115% avg frataxin increase; registrational study planned by early 2026.
- LX2020 (PKP2-ACM): Cohort 1 showed 71% and 115% PKP2 increases; enrolling cohort 3; interim update expected H2 2025.
- Redeployed $20M from non-cardiac pipeline; limited reduction in force of ~15% employees.

## SEC filing metadata
- accession: 0000950170-25-068534
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/0000950170-25-068534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025068534/lxeo-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068534
- JSON: https://secwatch.observer/filing/0000950170-25-068534.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.